Functionality of RV19BBCRTCR+ and RV19BBCRTRBC− CAR T cells in vivo. (A-H) NSG mice were injected IV with 1 × 105 NALM6, followed by an IV T-cell injection (2 × 107 cells) of untransduced T cells (n = 6), RV19BBCRTCR+ (n = 9), and RV19BBCRTRBC− CAR T cells (n = 6) 3 days after. (A,B) At the indicated time points after T-cell injection, NALM6 leukemia burden was monitored by BLI. (A) Exemplary bioluminescence pictures are shown, as well as (B) changes in NALM6 leukemia load for each mouse. (C) Kaplan-Meier analysis of survival of mice treated with 1 × 105 NALM6 cells (n = 6 per group) is shown. A log-rank Mantel-Cox test was used to test for statistical significance. (D) T-cell persistence in peripheral blood was measured by flow cytometry. A 2-tailed Mann-Whitney U test was performed to determine statistical significance. (E) Overview of the incidence of leukemia- or nonleukemia-related death in mice. (F) Body weight was monitored at several time points after T-cell injection. (G) Exemplary micrographs of skin tissue stained for CC3 by IHC are shown for mice treated with RV19BBCRTCR+ or RV19BBCRTRBC− CARs.